Multifocal Lens Centration and Its Effect on Visual Performance in a Presbyopic Population

Presbyopia Clinical Trial

— BUICK  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02228109
• Other study ID #: 20067
• Status: Completed
• Phase: N/A
• First received: August 26, 2014
• Last updated: May 28, 2015
• Start date: December 2014
• Est. completion date: April 2015

Study information

• Verified date: May 2015
• Source: University of Waterloo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review CommitteeCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to use a corneal topographer, a device that is readily available in most optometric practices, in order to determine the position of the multifocal (MF) contact lens (CL) optics in relation to the optics of the eye. The specific purpose of this study is to evaluate if there is a relationship between the positioning of the optics of the study lenses and the objective and subjective visual performance as well as participant satisfaction. The MF CL lenses will be fitted to two groups of participants (previously unsuccessful vs. currently successful MF CL wearers).

HYPOTHESES

• The measurement of the power distribution acquired from the Medmont E300 corneal topographer is effective in determining MF CL lens centration and is a predictor of MF CL success.

• There is a difference in MF CL centration, determined by corneal topography, between successful and unsuccessful MF CL wearers.

• MF CL centration, determined by corneal topography, is correlated with visual performance, determined by ocular aberrometry, measures of visual acuity and subjective satisfaction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 42 Years and older

Eligibility

Inclusion Criteria:

A person is eligible for inclusion in the study if he/she:

1. Is at least 42 years of age and has full legal capacity to volunteer;

2. Has read and signed an information consent letter;

3. Is willing and able to follow instructions and maintain the appointment schedule;

4. Has previous experience with wearing MF CLs;

5. Is able to be successfully fitted with all study lenses;

6. Has a vertex-corrected spherical distance prescription of +6.00 to 8.00D (inclusive) in both eyes;

7. Has a spectacle cylinder =0.75D in both eyes;

8. Requires a reading addition of =+1.00D;

Exclusion Criteria:

A person will be excluded from the study if he/she:

1. Is participating in any concurrent clinical or research study;

2. Has any known active* ocular disease and/or infection;

3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;

4. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;

5. Has a known sensitivity to the diagnostic pharmaceuticals to be used in the study;

6. Is pregnant, lactating or planning a pregnancy at the time of enrolment;

7. Is aphakic;

8. Has undergone refractive error surgery;

9. Has monocular best-corrected VA of worse than 20/30 in each eye;

10. Has amblyopia or strabismus;

11. Has anisometropia >2D between both eyes

• For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Presbyopia

Intervention

Device:
• Acuvue Oasys for Presbyopia
Acuvue Oasys for Presbyopia contact lenses worn
• PureVision2 for Presbyopia
PureVision2 for Presbyopia contact lenses worn
• Biofinity Multifocal
Biofinity Multifocal contact lenses worn

Locations

Country	Name	City	State
Canada	Centre for Contact Lens Research, University of Waterloo	Waterloo	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University of Waterloo	Johnson & Johnson Vision Care

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decentration	Decentration (in mm and axis of decentration) of the multifocal contact lens optical center relative to ocular reference points (e.g. the pupil center or the line of sight), determined using difference maps produced by the Medmont E300 corneal topographer.	Day 1	No
Secondary	Visual Acuity (high contrast) at distance	Visual Acuity (high contrast) (logMAR) at distance 6m	Day 1	No
Secondary	Visual Acuity (high contrast) at intermediate distance	Visual Acuity (high contrast) (logMAR) at intermediate distance 1m	Day 1	No
Secondary	Visual Acuity (high contrast) at near	Visual Acuity (high contrast) (logMAR) at near (0.4m)	Day 1	No
Secondary	Visual Acuity (low contrast) at distance	Visual Acuity (low contrast) at distance 6m	Day 1	No
Secondary	Visual Acuity (low contrast) at intermediate distance	Visual Acuity (low contrast) (logMAR) at intermediate distance 1m	Day 1	No
Secondary	Visual Acuity (low contrast) at near	Visual Acuity (low contrast) (logMAR) at near (0.4m)	Day 1	No
Secondary	Overall subjective rating of lens performance in real world tasks	Participants rate overall satisfaction with vision with the contact lenses on a scale of 0-100, where 0=completely dissatisfied and 100=completely satisfied, after completing a series of real world tasks.	Day 1	No
Secondary	Ocular aberrometry	Ocular aberrometry as measured by a LADARWave aberrometer	Day 1	No